Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF in children and adolescents with chronic hepatitis B
2023-506143-42-00Phase 2Suspended
- Sponsor
- Gilead Sciences
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of tenofovir alafenamide in Chronic Hepatitis B (CHB) (3 arms), sponsored by Gilead Sciences. Primary endpoints: Incidence of treatment-emergent serious adverse events, Incidence of treatment-emergent adverse events and 2 more. Started May 2018; status: suspended.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2023-506143-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506143-42-00.